Compare ADVB & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADVB | CWD |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | 31 | N/A |
| Industry | Medical Specialities | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 10.0M |
| IPO Year | N/A | 2022 |
| Metric | ADVB | CWD |
|---|---|---|
| Price | $7.78 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 723.8K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,097,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.17 |
| P/E Ratio | $1.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $0.47 |
| 52 Week High | $24.23 | $46.21 |
| Indicator | ADVB | CWD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.05 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $1.13 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 3.13 |
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.